Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

Authors:

Abstract
HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men. We previously analyzed 58 infections in the blinded phase of HPTN 083 (16 in the CAB arm and 42 in the TDF-FTC arm).
Funding Information
  • HHS | National Institutes of Health (UM1AI068619)
  • HHS | National Institutes of Health (UM1AI068617)
  • HHS | National Institutes of Health (UM1AI068613)
  • ViiV Healthcare
  • Gilead Sciences

This publication has 16 references indexed in Scilit: